TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33119467
Drug: 500 mg of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of aspirin (prostaglandin inhibition)
Study: 33516927
Drug: Indomethacin (IM)
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin (IM) oral spray
Study: 35236061
Drug: Low-frequency magnet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-frequency magnet therapy
Study: 34587382
Drug: AZD1222 (ChAdOx1
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1222 (ChAdOx1 nCoV-19) vaccine
Study: 32462773
Drug: Zonisamide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zonisamide (400 mg)
Study: 34162485
Drug: Warfarin (W)
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin (W)
Study: 35513795
Drug: Low-25(OH)D-Calcitriol group
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-25(OH)D-Calcitriol group (calcitriol 0.25 µg bid)
Study: 36208548
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBOT), 40 daily sessions
Study: 36064261
Drug: Intracytoplasmic Sperm
Normalized name: herring sperm DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracytoplasmic Sperm Injection (ICSI)
Study: 35394687
Drug: Spirulina (5.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirulina (5.7 g day-1)
Study: 34814585
Drug: 60 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 μg hepatitis B vaccine
Study: 32597821
Drug: Safe drug
Normalized name: Safe-Guard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safe drug management, error management, infection control, safe clinical services
Study: 32940428
Drug: Telemedicine (TM)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telemedicine (TM) service based on mobile health (mHealth), including remote daily monitoring of biometric data and symptom reporting combined with videoconference structured, nurse-based follow-up.
Study: 33787615
Drug: Pilates group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilates group (P-G)
Study: 33787615
Drug: General physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: General physical activity program group (Pa-G)
Study: 35623841
Drug: 6.3 g
Normalized name: OCTINOXATE 6.3 g in 100 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.3 g (Low) essential amino acid enriched whey protein supplement
Study: 35623841
Drug: 12.6 g
Normalized name: BENZOYL PEROXIDE 12.6 g in 113 g TOPICAL SOAP [PanOxyl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.6 g (High) essential amino acid enriched whey protein supplement
Study: 34586711
Drug: Curcumin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin supplementation (dose ≤1,000 mg/day)
Study: 34586711
Drug: Curcumin consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin consumption (less than 2000 mg/day)
Study: 33285707
Drug: Dexmedetomidine-propofol combination
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexmedetomidine-propofol combination (Group D)
Study: 34560383
Drug: Cisplatin 30
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 30 mg/m2 with nimotuzumab once a week with curative radiotherapy
Study: 34560383
Drug: Cisplatin 30
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 30 mg/m2 alone
Study: 36282170
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg intravenous tranexamic acid (TXA) administered 15 min before incision in 100 cc of saline
Study: 33109037
Drug: Desloratadine tablet
Normalized name: Desloratadine Tablets
DrugBank: Desloratadine (DB00967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desloratadine tablet (5mg)
Study: 35365713
Drug: Enema (maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enema (maintenance dose delivery)
Study: 33576545
Drug: Acetaminophen 650
Normalized name: acetaminophen 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 650 mg
Study: 36189948
Drug: 140 mg
Normalized name: caffeine 140 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 140 mg erenumab
Study: 33681652
Drug: Perampanel (2–12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel (2–12 mg/day)
Study: 36353577
Drug: Umbilical cord
Normalized name: Sus Scrofa Umbilical Cord
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umbilical cord blood infusion
Study: 32471645
Drug: Zymomonas mobilis
Normalized name: Laurus nobilis
DrugBank: Laurus nobilis (DB10670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zymomonas mobilis fermented broth twice a day
Study: 32471645
Drug: Cell-free fermented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cell-free fermented broth once daily
Study: 32471645
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline once daily)
Study: 32319087
Drug: Rocuronium administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium administration
Study: 34057705
Drug: 3 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/day green cardamom
Study: 34252289
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg dasiglucagon
Study: 32727732
Drug: Free glasses
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free glasses and a teacher incentive (tablet computer if ≥80% of children given glasses were wearing them on un‐announced examination)
Study: 32727732
Drug: Glasses prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glasses prescription and letter to parents
Study: 38178229
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D
Study: 36367720
Drug: Extended run-in
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended run-in varenicline treatment (4 weeks before quitting)
Study: 34342754
Drug: Self-administered gut-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered gut-directed hypnosis intervention (7 bi-weekly audio sessions over 3 months)
Study: 34342754
Drug: Self-administered gut-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered gut-directed hypnosis intervention
Study: 34521576
Drug: Peer-led theory-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer-led theory-based oral health intervention
Study: 34521576
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (booklets for oral health promotion)
Study: 33131932
Drug: Post F-subunit
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post F-subunit vaccine
Study: 33007285
Drug: Intravenous antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotics (ceftazidime and tobramycin for 14 days combined with inhaled colistimethate sodium for 12 weeks)
Study: 34836350
Drug: Insulin levels
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin levels in all conditions vs Sucralose
Study: 32215888
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus of 200 μg 25OHD followed by daily infusion of 15 μg 25OHD for 10 days
Study: 34857853
Drug: Carprofen 4.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carprofen 4.4 mg/kg/day for 90 days
Study: 34857853
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no anti-inflammatory medication)
Study: 32325373
Drug: macimorelin 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: macimorelin 0.5 mg/kg
Study: 32325373
Drug: macimorelin 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: macimorelin 1.0 mg/kg
Study: 32325373
Drug: macimorelin 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: macimorelin 2.0 mg/kg
Study: 34850166
Drug: Post-treatment biopsies
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment biopsies
Study: 36164180
Drug: Belantamab mafodotin
Normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Belantamab mafodotin 2.5 mg/kg Q3W (Arm A)
Study: 36164180
Drug: Belantamab mafodotin
Normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Belantamab mafodotin 1.9 mg/kg Q3W (Arm B)
Study: 36164180
Drug: Belantamab mafodotin
Normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Belantamab mafodotin 1.9 mg/kg Q6W (Arm D)
Study: 36164180
Drug: Belantamab mafodotin
Normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Belantamab mafodotin 1.9 mg/kg Q6W (Arm E)
Study: 34098672
Drug: Placebo vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vitamin C 100 mg
Study: 33545945
Drug: Pestle needle
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pestle needle therapy
Study: 32798197
Drug: Control (sham
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (sham treatment with very light pressure)
Study: 32861819
Drug: No radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No radiation therapy boost (641 patients, 59.2%)
Study: 32472958
Drug: Dexamethasone (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (16 mg intravenously at start of surgery)
Study: 32472958
Drug: Control (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (4 ml saline)
Study: 36124494
Drug: BCG vaccine
Normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG vaccine (low dose 0.01 mg and high dose 0.1 mg)
Study: 32270179
Drug: Insufficient 25(OH)D
Normalized name: 1α,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insufficient 25(OH)D (<32 ng/mL)
Study: 35413905
Drug: Intraperitoneal normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal normal saline instillation (INSI) of 15 mL/kg body weight
Study: 35413905
Drug: Conventional combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional combination of open laparoscopic trocar valves with gentle abdominal pressure
Study: 33539742
Drug: Standard combined-modality
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard combined-modality treatment (2 + 2 regimen followed by 30 Gy involved-field radiotherapy)
Study: 33539742
Drug: PET4-guided treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET4-guided treatment (2 + 2 regimen followed by 30 Gy of involved-node radiotherapy only if PET positive)
Study: 33539742
Drug: Standard combined-modality
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard combined-modality treatment
Study: 33539742
Drug: PET4-guided treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET4-guided treatment
Study: 36267888
Drug: Conventional therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapies (CT)
Study: 32866432
Drug: KRd regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: KRd regimen (36 mg/m2 of intravenous carfilzomib, 25 mg of oral lenalidomide, 40 mg of oral dexamethasone)
Study: 32866432
Drug: VRd regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRd regimen (1.3 mg/m2 of bortezomib, 25 mg of oral lenalidomide, 20 mg of oral dexamethasone)
Study: 35528160
Drug: bismuth quadruple
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bismuth quadruple therapy (BQT)
Study: 35315909
Drug: Anticoagulant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant therapy for 6 weeks
Study: 37098453
Drug: Clindamycin gel
Normalized name: clindamycin Topical Gel
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin gel
Study: 35181350
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (Con)
Study: 32510696
Drug: 750 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg/kg/day of placebo-control
Study: 33006975
Drug: GARCH models
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: GARCH models with innovations following the compound distributions
Study: 35345897
Drug: Robotic self-training
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic self-training (ReoGo-J) plus conventional therapy (robotic therapy)
Study: 35345897
Drug: Conventional self-training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional self-training plus conventional therapy (control)
Study: 35851754
Drug: Telitacicept 240
Normalized name: Telitacicept
DrugBank: Telitacicept (DB18312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telitacicept 240 mg every week for 46 times after plasma exchange
Study: 34504196
Drug: Oral rifaximin
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral rifaximin (550 mg twice daily for 7-10 or 14-21 days preoperatively and 7 days postoperatively)
Study: 34504196
Drug: Oral rifaximin
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral rifaximin
Study: 35475907
Drug: 80 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 µg dasiglucagon (D80)
Study: 35475907
Drug: 120 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 µg dasiglucagon (D120)
Study: 33629506
Drug: Caloric restriction
Normalized name: Chloric acid
DrugBank: Chloric acid (DB14150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caloric restriction diet with fiber supplementation (10 g day-1 inulin + 10 g day-1 resistant maltodextrin)
Study: 33185050
Drug: 40 mg/m²
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/m² PLD (experimental arm)
Study: 33185050
Drug: 50 mg/m²
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/m² PLD (standard arm)
Study: 32972635
Drug: 5% Pueraria
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% Pueraria mirifica gel
Study: 35212470
Drug: Drug use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug use
Study: 35710599
Drug: Liraglutide 3
Normalized name: liraglutide 3.6 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 3 mg (LIRA 3 mg)
Study: 34499672
Drug: Metformin (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (2000 mg/day)
Study: 33625251
Drug: Drug targets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug targets identified
Study: 34694880
Drug: Ruxolitinib (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib (20 mg)
Study: 34694880
Drug: Artemether-Lumefantrine (80/480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-Lumefantrine (80/480 mg)
Study: 32412683
Drug: Tertiary-hospital specialist
Normalized name: Prednisolone tertiary butylacetate
DrugBank: Prednisolone tebutate (DB14632)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tertiary-hospital specialist allergy clinic (CC)
Study: 36073634
Drug: Intravenous nicorandil
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nicorandil (6 mg bolus followed by 6 mg/h infusion)
Study: 32555148
Drug: Mixed Meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed Meal (MM) - 120 mL, 523 kJ (125 kcal) four times/day for 14 days
Study: 32555148
Drug: Electrolyte Solution
Normalized name: electrolyte solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrolyte Solution (ES) - 50 kJ (12 kcal) four times/day for 14 days
Study: 32365097
Drug: Astodrimer 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astodrimer 0.5% Gel
Study: 32365097
Drug: Astodrimer 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astodrimer 3% Gel
Study: 36147650
Drug: Waiting-list control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting-list control group (maintained usual daily routines for 12 weeks)
Study: 36809247
Drug: Directly observed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directly observed treatment
Study: 35786002
Drug: Tenecteplase (exact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenecteplase (exact dosage not specified)
Study: 33835016
Drug: Reference product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference product (4 mg pridinol mesylate)
Study: 35783246
Drug: Anti-inflammatory treatment
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-inflammatory treatment
Study: 33855195
Drug: Continuous Positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Positive Airway Pressure (CPAP) therapy for 12 weeks
Study: 35233755
Drug: Trastuzumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab + chemotherapy
Study: 36482326
Drug: Ivermectin plus
Normalized name: clorsulon / ivermectin Injectable Solution [Ivermax Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin plus acetaminophen
Study: 35242882
Drug: C. lacerata
Approvals — FDA: no, EMA: no, PMDA: no
Description: C. lacerata (500 mg/capsule) for 12 weeks
Study: 33681744
Drug: Intramuscular haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular haloperidol
Study: 33556391
Drug: Large portion
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large portion (200 g) consumed at home
Study: 33556391
Drug: Small portion
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small portion (100 g) consumed at home
Study: 33556391
Drug: Large portion
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large portion (200 g) consumed in laboratory
Study: 33556391
Drug: Small portion
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small portion (100 g) consumed in laboratory
Study: 33482315
Drug: Ammoxetine 2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ammoxetine 2.5, 7.5, 15, 30, 45, 65, 100 mg (single-dose)
Study: 33482315
Drug: Ammoxetine 15,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ammoxetine 15, 30, 45 mg (multiple-dose for 8 days)
Study: 33482315
Drug: Placebo (single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (single-dose and multiple-dose)
Study: 34221032
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene regimen (OHR) including bioavailable stannous fluoride dentifrice, oscillating‐rotating electric toothbrush, cetylpyridinium chloride rinse, and floss
Study: 34990712
Drug: ABCC1 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ABCC1 inhibitor probenecid
Study: 35555189
Drug: Caffeine (CAF:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (CAF: 400 mg/day + 5 g/day of maltodextrin)
Study: 35555189
Drug: Creatine Nitrate
DrugBank: Creatine (DB00148)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Creatine Nitrate + Caffeine (CN+CAF: 5 g/day of creatine nitrate + 400 mg/day of caffeine)
Study: 35555189
Drug: Placebo (PL:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL: 5.4 g/day of maltodextrin)
Study: 36252718
Drug: Dexamethasone 24
Normalized name: dexAMETHasone 24 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 24 mg IV (perioperatively)
Study: 35366574
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg AZ-009
Study: 35130086
Drug: Epidural Morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural Morphine (5 mg) and Bupivacaine (0.25%, 2 mL)
Study: 33975325
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein (HP) diet (1.5 g protein/kg body weight)
Study: 33975325
Drug: Normal protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal protein (NP) diet (0.8 g protein/kg body weight)
Study: 35382844
Drug: Placebo infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusions followed by ATI
Study: 35382844
Drug: Dual long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual long-acting bNAbs infusions
Study: 33717406
Drug: Vigabatrin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin therapy
Study: 39466816
Drug: Azithromycin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (single dose)
Study: 34462986
Drug: Radiomics model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiomics model based on T2WI + DWI (combination)
Study: 33595427
Drug: 5% lidocaine
Normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% lidocaine cream applied perianally for 10 minutes (group 1)
Study: 33595427
Drug: 1% lidocaine
Normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lidocaine nerve block plus 5% lidocaine cream applied perianally for 10 minutes (group 2)
Study: 33595427
Drug: 1% lidocaine
Normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lidocaine nerve block plus 5% lidocaine cream applied perianally for 20 minutes (group 3)
Study: 33595427
Drug: 1% lidocaine
Normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lidocaine nerve block plus 5% lidocaine cream applied perianally and internally for 10 minutes (group 4)
Study: 33595427
Drug: 1% lidocaine
Normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lidocaine nerve block plus 5% lidocaine cream applied perianally and internally for 20 minutes (group 5)
Study: 33595427
Drug: 1% lidocaine
Normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lidocaine nerve block plus 5% lidocaine cream applied perianally and internally for 10 minutes (group 6)
Study: 34782430
Drug: Dendritic cell
Normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dendritic cell vaccine targeting tumor blood vessel antigens with immediate dasatinib (Arm B)